Alison R. Sehgal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning et al. · The Lancet · 2020 · 2.3K citations

Medicine, Oncology, Pharmacology +13

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil, Michael D. Jain, Lei Feng et al. · Journal of Clinical Oncology · 2020 · 786 citations · Full text

Medicine, Hematology, Oncology +17

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal et al. · The Lancet Oncology · 2021 · 617 citations

Medicine, Oncology, Pharmacology +13

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell et al. · The Lancet Oncology · 2022 · 234 citations

Medicine, Hematology, Oncology +14

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Anthony R. Mato, Chadi Nabhan, Paul M. Barr et al. · Blood · 2016 · 189 citations · Full text

Medicine, Oncology, Pharmacotherapy +13